Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessEGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
We aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in pancreatic cancer (PC) patients treated with the anti-EGFR agent erlotinib within the phase 3 randomised AIO-PK0104 s...
-
Chapter
Anti-MOG Antibodies as Early Predictors for Conversion to Relapsing-Remitting Disease Course in Patients Suggestive of Multiple Sclerosis
Multiple sclerosis (MS) is the most common neurological disease in young adults, with the potential for subsequent chronic functional impairment and disability. MS exhibits not only heterogeneous clinical mani...